The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease

Hussein N. Yassine, Varun Rawat, Wendy J. Mack, Joseph Quinn, Karin Yurko-Mauro, Eileen Bailey-Hall, Paul S. Aisen, Helena C. Chui, Lon S. Schneider

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Apolipoprotein E (APOE) ϵ4 and low cerebrospinal fluid (CSF) amyloid-β42 (Aβ42) levels are predictors for developing Alzheimer's disease (AD). The results of several studies indicate an interaction between docosahexaenoic acid (DHA) consumption and cognitive outcomes by APOE genotype. Our objective in the present study was to examine whether APOE ϵ4 genotype and low CSF Aβ42 levels were associated with reduced delivery of DHA to CSF in the Alzheimer's Disease Cooperative Study-sponsored DHA clinical trial. Methods: Phospholipid DHA was assayed in the plasma of 384 participants and CSF of 70 participants at baseline. Forty-four of the 70 participants completed the 18-month follow-up visit after allocation to placebo (n = 15) or DHA (n = 29). Plasma and CSF DHA levels, CSF Aβ42, Tau, and phosphorylated Tau were measured at baseline and after the 18-month intervention. Participants were divided into tertiles based on baseline Aβ42 CSF levels. To assess DHA delivery across the blood-brain barrier, the ratio of CSF to plasma DHA levels was calculated. Results: At baseline, there were no significant differences between CSF or plasma phospholipid DHA levels by CSF Aβ42 tertiles or ϵ4 status. After 18 months of DHA supplementation, participants at the lowest Aβ42 tertile had significantly lower CSF DHA levels (p = 0.01) and lower CSF-to-plasma DHA ratios (p = 0.05) compared to the other tertiles. Baseline CSF Aβ42 levels were significantly lower in ϵ4 carriers than in ϵ4 noncarriers (p = 0.01). Participants carrying the ϵ4 allele (n = 25) demonstrated a less pronounced increase in CSF DHA level compared with noncarriers (n = 4), with a possible interaction effect between treatment and APOE genotype (p = 0.07). Conclusions: APOE ϵ4 allele and lower CSF Aβ42 levels were associated with less transport of DHA to CSF. Brain amyloid pathology may limit the delivery of DHA to the brain in AD. Trial Registration: Clinicaltrials.gov identifier: NCT00440050. Registered on 22 Feb 2007.

Original languageEnglish (US)
Article number25
JournalAlzheimer's Research and Therapy
Volume8
Issue number1
DOIs
StatePublished - Jun 30 2016

Fingerprint

Docosahexaenoic Acids
Apolipoproteins E
Cerebrospinal Fluid
Alzheimer Disease
Genotype
Amyloid
Apolipoprotein E4
Phospholipids
Alleles
Brain
Blood-Brain Barrier

Keywords

  • Alzheimer's disease
  • Amyloid
  • APOE
  • Cerebrospinal fluid

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Cognitive Neuroscience

Cite this

The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. / Yassine, Hussein N.; Rawat, Varun; Mack, Wendy J.; Quinn, Joseph; Yurko-Mauro, Karin; Bailey-Hall, Eileen; Aisen, Paul S.; Chui, Helena C.; Schneider, Lon S.

In: Alzheimer's Research and Therapy, Vol. 8, No. 1, 25, 30.06.2016.

Research output: Contribution to journalArticle

Yassine, HN, Rawat, V, Mack, WJ, Quinn, J, Yurko-Mauro, K, Bailey-Hall, E, Aisen, PS, Chui, HC & Schneider, LS 2016, 'The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease', Alzheimer's Research and Therapy, vol. 8, no. 1, 25. https://doi.org/10.1186/s13195-016-0194-x
Yassine, Hussein N. ; Rawat, Varun ; Mack, Wendy J. ; Quinn, Joseph ; Yurko-Mauro, Karin ; Bailey-Hall, Eileen ; Aisen, Paul S. ; Chui, Helena C. ; Schneider, Lon S. / The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. In: Alzheimer's Research and Therapy. 2016 ; Vol. 8, No. 1.
@article{80173aa90509489585549a355144a64f,
title = "The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease",
abstract = "Background: Apolipoprotein E (APOE) ϵ4 and low cerebrospinal fluid (CSF) amyloid-β42 (Aβ42) levels are predictors for developing Alzheimer's disease (AD). The results of several studies indicate an interaction between docosahexaenoic acid (DHA) consumption and cognitive outcomes by APOE genotype. Our objective in the present study was to examine whether APOE ϵ4 genotype and low CSF Aβ42 levels were associated with reduced delivery of DHA to CSF in the Alzheimer's Disease Cooperative Study-sponsored DHA clinical trial. Methods: Phospholipid DHA was assayed in the plasma of 384 participants and CSF of 70 participants at baseline. Forty-four of the 70 participants completed the 18-month follow-up visit after allocation to placebo (n = 15) or DHA (n = 29). Plasma and CSF DHA levels, CSF Aβ42, Tau, and phosphorylated Tau were measured at baseline and after the 18-month intervention. Participants were divided into tertiles based on baseline Aβ42 CSF levels. To assess DHA delivery across the blood-brain barrier, the ratio of CSF to plasma DHA levels was calculated. Results: At baseline, there were no significant differences between CSF or plasma phospholipid DHA levels by CSF Aβ42 tertiles or ϵ4 status. After 18 months of DHA supplementation, participants at the lowest Aβ42 tertile had significantly lower CSF DHA levels (p = 0.01) and lower CSF-to-plasma DHA ratios (p = 0.05) compared to the other tertiles. Baseline CSF Aβ42 levels were significantly lower in ϵ4 carriers than in ϵ4 noncarriers (p = 0.01). Participants carrying the ϵ4 allele (n = 25) demonstrated a less pronounced increase in CSF DHA level compared with noncarriers (n = 4), with a possible interaction effect between treatment and APOE genotype (p = 0.07). Conclusions: APOE ϵ4 allele and lower CSF Aβ42 levels were associated with less transport of DHA to CSF. Brain amyloid pathology may limit the delivery of DHA to the brain in AD. Trial Registration: Clinicaltrials.gov identifier: NCT00440050. Registered on 22 Feb 2007.",
keywords = "Alzheimer's disease, Amyloid, APOE, Cerebrospinal fluid",
author = "Yassine, {Hussein N.} and Varun Rawat and Mack, {Wendy J.} and Joseph Quinn and Karin Yurko-Mauro and Eileen Bailey-Hall and Aisen, {Paul S.} and Chui, {Helena C.} and Schneider, {Lon S.}",
year = "2016",
month = "6",
day = "30",
doi = "10.1186/s13195-016-0194-x",
language = "English (US)",
volume = "8",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease

AU - Yassine, Hussein N.

AU - Rawat, Varun

AU - Mack, Wendy J.

AU - Quinn, Joseph

AU - Yurko-Mauro, Karin

AU - Bailey-Hall, Eileen

AU - Aisen, Paul S.

AU - Chui, Helena C.

AU - Schneider, Lon S.

PY - 2016/6/30

Y1 - 2016/6/30

N2 - Background: Apolipoprotein E (APOE) ϵ4 and low cerebrospinal fluid (CSF) amyloid-β42 (Aβ42) levels are predictors for developing Alzheimer's disease (AD). The results of several studies indicate an interaction between docosahexaenoic acid (DHA) consumption and cognitive outcomes by APOE genotype. Our objective in the present study was to examine whether APOE ϵ4 genotype and low CSF Aβ42 levels were associated with reduced delivery of DHA to CSF in the Alzheimer's Disease Cooperative Study-sponsored DHA clinical trial. Methods: Phospholipid DHA was assayed in the plasma of 384 participants and CSF of 70 participants at baseline. Forty-four of the 70 participants completed the 18-month follow-up visit after allocation to placebo (n = 15) or DHA (n = 29). Plasma and CSF DHA levels, CSF Aβ42, Tau, and phosphorylated Tau were measured at baseline and after the 18-month intervention. Participants were divided into tertiles based on baseline Aβ42 CSF levels. To assess DHA delivery across the blood-brain barrier, the ratio of CSF to plasma DHA levels was calculated. Results: At baseline, there were no significant differences between CSF or plasma phospholipid DHA levels by CSF Aβ42 tertiles or ϵ4 status. After 18 months of DHA supplementation, participants at the lowest Aβ42 tertile had significantly lower CSF DHA levels (p = 0.01) and lower CSF-to-plasma DHA ratios (p = 0.05) compared to the other tertiles. Baseline CSF Aβ42 levels were significantly lower in ϵ4 carriers than in ϵ4 noncarriers (p = 0.01). Participants carrying the ϵ4 allele (n = 25) demonstrated a less pronounced increase in CSF DHA level compared with noncarriers (n = 4), with a possible interaction effect between treatment and APOE genotype (p = 0.07). Conclusions: APOE ϵ4 allele and lower CSF Aβ42 levels were associated with less transport of DHA to CSF. Brain amyloid pathology may limit the delivery of DHA to the brain in AD. Trial Registration: Clinicaltrials.gov identifier: NCT00440050. Registered on 22 Feb 2007.

AB - Background: Apolipoprotein E (APOE) ϵ4 and low cerebrospinal fluid (CSF) amyloid-β42 (Aβ42) levels are predictors for developing Alzheimer's disease (AD). The results of several studies indicate an interaction between docosahexaenoic acid (DHA) consumption and cognitive outcomes by APOE genotype. Our objective in the present study was to examine whether APOE ϵ4 genotype and low CSF Aβ42 levels were associated with reduced delivery of DHA to CSF in the Alzheimer's Disease Cooperative Study-sponsored DHA clinical trial. Methods: Phospholipid DHA was assayed in the plasma of 384 participants and CSF of 70 participants at baseline. Forty-four of the 70 participants completed the 18-month follow-up visit after allocation to placebo (n = 15) or DHA (n = 29). Plasma and CSF DHA levels, CSF Aβ42, Tau, and phosphorylated Tau were measured at baseline and after the 18-month intervention. Participants were divided into tertiles based on baseline Aβ42 CSF levels. To assess DHA delivery across the blood-brain barrier, the ratio of CSF to plasma DHA levels was calculated. Results: At baseline, there were no significant differences between CSF or plasma phospholipid DHA levels by CSF Aβ42 tertiles or ϵ4 status. After 18 months of DHA supplementation, participants at the lowest Aβ42 tertile had significantly lower CSF DHA levels (p = 0.01) and lower CSF-to-plasma DHA ratios (p = 0.05) compared to the other tertiles. Baseline CSF Aβ42 levels were significantly lower in ϵ4 carriers than in ϵ4 noncarriers (p = 0.01). Participants carrying the ϵ4 allele (n = 25) demonstrated a less pronounced increase in CSF DHA level compared with noncarriers (n = 4), with a possible interaction effect between treatment and APOE genotype (p = 0.07). Conclusions: APOE ϵ4 allele and lower CSF Aβ42 levels were associated with less transport of DHA to CSF. Brain amyloid pathology may limit the delivery of DHA to the brain in AD. Trial Registration: Clinicaltrials.gov identifier: NCT00440050. Registered on 22 Feb 2007.

KW - Alzheimer's disease

KW - Amyloid

KW - APOE

KW - Cerebrospinal fluid

UR - http://www.scopus.com/inward/record.url?scp=84976402651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976402651&partnerID=8YFLogxK

U2 - 10.1186/s13195-016-0194-x

DO - 10.1186/s13195-016-0194-x

M3 - Article

VL - 8

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

SN - 1758-9193

IS - 1

M1 - 25

ER -